The Captopril Prevention Project (CAPPP) in hypertension--baseline data and current status

Area of Science:

• Cardiology
• Pharmacology
• Hypertension Research

Background:

• Hypertension is a major risk factor for cardiovascular disease.
• Conventional therapies like diuretics and beta-blockers have limitations.
• Angiotensin-converting enzyme (ACE) inhibitors show potential benefits on intermediary cardiovascular endpoints.

Purpose of the Study:

• To compare captopril-based treatment with conventional antihypertensive therapy in hypertensive patients.
• To evaluate the effects of ACE inhibition on cardiovascular morbidity and mortality.
• To investigate the impact of captopril on blood pressure and other cardiovascular risk factors.

Main Methods:

• Prospective, randomized, open, blinded-endpoint evaluation (PROBE) study design.
• Inclusion of 11,019 hypertensive patients in Sweden and Finland.
• Randomization to conventional therapy (diuretics/beta-blockers) or captopril-based treatment.

Main Results:

• First-year data shows an average blood pressure reduction of 11/8 mm Hg.
• Substudies explored insulin sensitivity, ACE gene polymorphisms, and renal function.
• Ongoing substudies investigate various aspects of ACE inhibition in hypertension.

Conclusions:

• Captopril-based treatment effectively reduces blood pressure in hypertensive patients.
• ACE inhibitors may offer superior cardiovascular risk reduction compared to conventional therapies.
• Further results from the CAPPP study are anticipated to provide comprehensive insights.